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Representativeness of ‘standard’ antihypertensive drug trials is uncertain, with limited recruitment 41 
of older-people. Some trials specifically recruit older participants to address this. If such older-42 
people’s trials are representative, we would expect rates of hospitalisation and death in each trial to 43 
be similar to community rates, and higher than rates in standard trials. 44 
Methods 45 
We identified trials of Renin-Angiotensin-Aldosterone system (RAAS) drugs for hypertension. Serious 46 
Adverse Events (SAEs) are routinely included in trial reports and are predominantly accounted for by 47 
all-cause hospitalisations and death.  We compared SAE rates in older-people’s and standard trials, 48 
adjusting for trial characteristics (phase/drug/comparison/outcome). We identified a community 49 
cohort of adults with hypertension commencing similar drugs to obtain an expected rate of 50 
hospitalisations/deaths, and compared this to observed SAE rates in each trial.  51 
Results 52 
Included 110 trials: 11 older-people’s trials exclusively recruited people over 60 years; 99 standard 53 
trials included general adult populations (over and under 60-years). Older-people’s trials had higher 54 
SAEs rate than standard trials (0.18 versus 0.11 events/person/year, adjusted IRR 1.74, 95% CI 1.03-55 
2.92). The hospitalisation and death rate in the community for those taking RAAS antihypertensives 56 
was much greater than the rate of SAEs reported in standard (ratio 3.70 (3.12-4.55)) and older-57 
people’s trials (4.35 (2.56-7.69)), adjusting for age and sex.  58 
Discussion 59 
Trials report substantially fewer SAEs than expected from rates of hospitalisations and deaths among 60 
similar-aged people receiving equivalent treatments in the community. SAE rates may be a useful 61 
metric to assess trial representativeness. Clinicians should be cautious when applying trial 62 




Wellcome Trust, MRC.  65 
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Research in Context 66 
Evidence before this study 67 
We searched Medline from inception to 5th November 2020 without language restriction using terms 68 
for “hypertension” and “trials”, and (“representative*” or “serious adverse events”) for studies 69 
assessing representativeness of hypertension trial populations or assessing the rates of SAEs in 70 
hypertension trials. Four studies, including 24 different trials, assessed the representativeness of 71 
hypertension trials by applying trial exclusion criteria to people with hypertension in routine clinical 72 
practice. The proportion of people who were ineligible for trials was between 50% and 100% in most 73 
cases. This was true of trials specifically focussing on older adults (e.g. HYVET, SPRINT and OPTiMISE 74 
trials) in which polypharmacy, multimorbidity and frailty were associated with ineligibility. This 75 
suggests that trial participants are likely to be ‘healthier’ overall than people treated in the 76 
community. Previous studies have not directly compared health-related outcomes of trial 77 
participants to real-world populations. Older adults have been shown to have higher rates, and a 78 
greater diversity, of adverse events in the trial setting. However, we did not identify any previous 79 
studies that systematically assessed rates of SAEs in hypertension trials; that compared SAEs in trials 80 
focussing on older people with other trials; or that compared SAEs in the trial population to similar 81 
events in community populations.  82 
What this study adds 83 
After systematically identifying hypertension trials of drugs acting on the renin-angiotensin-84 
aldosterone system, we demonstrated that trials focussing on older people had a significantly higher 85 
rate of SAEs than comparator ‘standard’ trials which did not focus specifically on older people. As 86 
would be expected, this suggests that trials focussing on older people recruited people with a 87 
greater risk of adverse health outcomes than trials including all ages. However, the rate of all-cause 88 
hospitalisations and deaths (which, by definition, would be SAEs in trial populations) among people 89 
with hypertension treated in the community was on average four-times higher than the SAE rate in 90 
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the trials, after adjusting for age and sex. This difference was similar for standard trials and trials 91 
focusing on older people. Therefore, despite having a higher risk of SAEs than in standard trials, 92 
people included in hypertension trials focused on older people have a considerably lower incidence 93 
of adverse health outcomes than people of a similar age, receiving similar treatment in the 94 
community. This demonstrates that there are clinically meaningful differences between trial 95 
populations and people treated for hypertension in the community. Furthermore, where SAE rates 96 
in trials are lower than expected, this should prompt careful consideration of trial exclusion criteria 97 
and population characteristics when assessing representativeness and applicability. 98 
Implications of all the available evidence 99 
Our findings demonstrate that people in hypertension trials experience substantially lower rates of 100 
adverse health outcomes than people with hypertension treated with similar drugs in the 101 
community. This adds weight to the body of evidence showing that hypertension trials are under-102 
representative of their target populations. However, our findings also add nuance to this statement, 103 
as trials focussing on older people do have a significantly higher rate of SAEs than standard trials. 104 
Therefore, trials focussing on older people do, at least in part, reflect the increased risk of adverse 105 
outcomes seen in older populations. Trials focussing on older people therefore have an important 106 
role in informing treatment decisions in older people, but should be viewed with caution as, like 107 
standard trials, they are not representative of community populations. Our findings also indicate 108 
that SAE rates should be considered as a novel metric with which to assess the representativeness of 109 
trial populations, through comparison with the incidence of similar events in routine clinical care. 110 
Such an approach could facilitate more direct quantification of the consequences of trial under-111 
representativeness, however this would require consistent and complete recording and reporting of 112 




Hypertension is a common and important modifiable risk factor for major cardiovascular disease. 115 
Hypertension is associated with age, with over 75% of people over 80 years old diagnosed with 116 
hypertension.1 There is uncertainty, however, about how hypertension should best be managed in 117 
older people.2 The risk of cardiovascular disease associated with hypertension may reduce as people 118 
age,3 particularly in the context of frailty.4 Furthermore, antihypertensive treatment presents a 119 
range of potential risks which may disproportionately impact older people.  120 
Whilst randomised controlled trials provide the least biased estimates of treatment efficacy, there 121 
are concerns that trial participants are often not representative of people treated for hypertension 122 
in routine clinical practice.5 Specifically, older people are often excluded from trials.6 This can occur 123 
directly, through age-based exclusion criteria, or indirectly through other exclusion criteria (e.g. 124 
comorbidity or co-prescribing) as well as the trial recruitment process.6,7 To address this problem 125 
and provide evidence to guide treatments of older people, some trials have focussed explicitly on 126 
older people.8,9 However, such trials often only enrol a fraction of those invited to participate.10  127 
Consequently, it remains unclear whether conducting trials specifically among older people is 128 
sufficient to overcome the difficulties in applying trial evidence to older people encountered in 129 
routine clinical practice.  130 
 Older people have a greater risk of adverse health outcomes in routine care settings, and in trials.11 131 
This is likely to be driven by characteristics such as frailty, multimorbidity (increasing the risk of drug-132 
disease interactions) and polypharmacy (increasing risk of drug-drug interactions), and decreased 133 
kidney and liver function. All are more common in older age, associated with poor health outcomes, 134 
and often under-represented within trials.12-16  135 
Previous studies assessing trial representativeness have tended to apply trial exclusion criteria to 136 
population samples derived from routine healthcare data or disease registries, concluding that many 137 
people living with long-term conditions would be ineligible for trials.5,6,10,17 However, such an 138 
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approach does not directly assess the health outcomes in trial participants compared to those 139 
receiving routine care. One potential alternative approach is to analyse Serious Adverse Events 140 
(SAEs). SAEs in a trial setting are events which are either life threatening, lead to death, cause or 141 
prolong hospitalisation, result in serious or lasting impairment or disability, or cause a birth defect. 142 
Regulatory bodies require that trial sponsors record and report all SAEs,18 while recording SAEs is 143 
also part of the CONSORT statement for the publication of trial findings.19 Importantly, SAEs are 144 
required to be reported irrespective of the suspected cause, as well as for both treatment and 145 
control arms. Therefore, SAEs should provide a reliable measure of the rate of adverse health 146 
outcomes (particularly resulting in hospitalisation and death) within a trial population. Indeed, if a 147 
trial was perfectly representative, we would expect the SAE rate of that trial to be similar to 148 
hospitalisation and death rates among the “target” patients with the same condition to which we 149 
would hope to apply the trial results. We would also expect trials involving older people to have 150 
higher SAE rates than trials for the same indication recruiting a more general adult population. 151 
The aim of this paper is to compare the rates of SAEs in trials of older people with the rates in trials 152 
not focussing specifically on older people (‘standard trials’) and compare these findings to the rate of 153 
SAEs (i.e. rate of hospitalisation and death) in people with hypertension starting a similar treatment 154 
in routine clinical practice, adjusting for age and sex. As an exemplar, here we focus on drugs to treat 155 
hypertension acting on the renin-angiotensin-aldosterone system (RAAS). RAAS drugs were chosen 156 
as they are commonly used to treat hypertension, including in older people. There are also concerns 157 
that older people are under-represented in RAAS trials.5,17,20 Furthermore, associated risks such as 158 
renal dysfunction, orthostatic hypotension, syncope, and polypharmacy are likely to be greater in 159 
older people.21  160 




This study compares SAE rates in registered randomised controlled trials of RAAS drugs to treat 163 
hypertension with a community sample of people with hypertension who were initiated on RAAS 164 
drugs 165 
Study design and participants 166 
Trials were identified from an extract on 1st August 2017 of all clinical trials registered at 167 
clinicaltrials.gov (a registry of clinical trials from across the world managed by the United States 168 
National Institutes of Health), to which we had applied World Health Organisation Anatomic 169 
Therapeutic Chemical (WHO ATC) drug classes for all interventions.12  To be eligible, trials had to be 170 
registered from 1999 onwards, be phase 2-3, 3, or 4, have eligibility criteria published in English, and 171 
be evaluating RAAS drugs for the treatment of hypertension. We included trials in two stages (Figure 172 
1). First, we identified all trials with a minimum inclusion age of 60-years or older and defined these 173 
as trials of older people. We reviewed these to identify drugs and indications for which such trials 174 
were commonly undertaken. Secondly, we obtained, as a comparator group, all ‘standard’ trials for 175 
the same indications and drugs with a minimum inclusion age <60 years. We included trials 176 
undertaken in any country, single- or multi-centre trials, with published or unpublished results.  177 
  178 
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Figure 1: 179 
 180 
Legend: “Missing” refers to the fact that the entry for the specific field in clincialtrials.gov for the minimum age was 181 
missing. The full text of the trial registration was then reviewed to identify if the trial was targeted specifically at older 182 
participants.  a) All RAAS drugs were permitted for the selection of eligible older people trials. Only trials which were 183 
studied in one or more of the older person trials (aliskiren, irbesartan, olmesartan, telmisartan or valsartan) were selected 184 
for the comparator group of the standard trials. b) Within drug comparisons refers to trials where all arms included the 185 
same drug (eg trials of different dosages or regimens). Between class comparisons refers to trials where all arms included 186 
drugs with the same 5-character ATC class (eg drugs in WHO ATC class C09CA are all angiotensin II receptor blockers). 187 
 188 
  189 
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The community comparison sample was identified using the Secure Anonymised Information 190 
Linkage (SAIL) databank. SAIL collects routine healthcare data (including primary care diagnostic 191 
codes and prescriptions, with linked hospital and mortality data) from participating practices in 192 
Wales, UK (covering approximately 70% of the Welsh population). SAIL participants are 193 
representative of the Welsh population in terms of age, sex and socioeconomic status. We identified 194 
participants with a previous diagnostic code for hypertension in primary care who were prescribed a 195 
RAAS drug for the first time. We excluded participants who registered with a SAIL practice less than 196 
12 months before starting the RAAS drug. We also excluded people with any coded myocardial 197 
infarction or stroke occurring in the 12 months prior to initiation (as these people were unlikely to 198 
be receiving the RAAS drug solely to treat hypertension, so are likely to have higher rates of 199 
hospitalisation and death). Figure 2 summarises participant selection and exclusions. As a sensitivity 200 
analysis, we also excluded all SAIL participants with a previous code for diabetes mellitus, chronic 201 
kidney disease, or heart failure. 202 
  203 
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Figure 2: Inclusion and analysis of SAIL participants for community comparison 204 
 205 
  206 
Adult SAIL participants, initial prescription for RAAS drug 2011-2015  
N=111,653 
Diagnostic code of hypertension at any time before prescription 
N=70,083 
No myocardial infarction or stroke past 12 months 
N=68,336 
Registered for at least 12 months 
N=56,036 
56,036 participants with any previous hypertension code 
  Mean age: 60.6 (13.9) 
  28,167 (50.3%) female 
  26,173 events (hospitalization/death) 
 
3 years follow-up 
Mean observation time 2.8 years per person         
Censored at death or de-registration 
Time 
Exclude recent 
MI, stroke, or  
recent 
registrations 
12-month  Incident RAAS prescription    3 years follow-up 
look-back 
41,570 excluded  
No hypertension 
1,747 excluded  
Recent MI/stroke 
12,300 excluded  
Recently registered 




For the trials we extracted the following information from clinicaltrials.gov, clinical trial reports and 208 
published papers (all data on https://github.com/dmcalli2/adverse_events_older_people): baseline 209 
characteristics of the trial participants (age, sex, body mass index), number of trial participants, trial 210 
phase, trial drug, comparison treatment, outcomes, follow up times, and the occurrence of serious 211 
adverse events (total number of events). SAE reporting is a regulatory requirement for trials,18 with 212 
SAEs defined as any event which is life threatening, leads to hospitalisation or death, results in 213 
serious or lasting impairment or disability, or causes a birth defect.22 Among these, hospitalisations 214 
and deaths are the most common. We also recorded whether the trial outcome was a hard outcome 215 
(i.e. a clinical endpoint such as major adverse cardiovascular event or mortality), or soft outcome 216 
(i.e. a surrogate marker such as change in blood pressure). For trials with hard outcomes, the 217 
number of clinical endpoint events was added to the number of SAEs before comparing event rates 218 
to the community population (as both endpoint and SAEs are likely to represent hospitalisation or 219 
deaths). We included SAEs and clinical endpoints from both the treatment and control arms of each 220 
trial, as most SAEs in the trial setting are not specifically related to the trial treatment.23 To confirm 221 
this, we also compared SAE rates in the treatment and placebo arms. 222 
For each participant in the community sample we identified age and sex. We then calculated the 223 
number of emergency/urgent hospitalisations (excluding elective admissions) or deaths occurring 224 
over 3 years follow-up. Participants were censored at death or if they de-registered from a 225 
participating practice within the 3-year period. 226 
Statistical analyses 227 
Our first analysis compared the SAE rate in trials of older people with standard trials, adjusting for 228 
trial characteristics. We modelled SAEs on older people trial status using hierarchical Poisson 229 
regression models (random intercept, Poisson likelihood); unadjusted (offset by estimated person 230 
time (calculated as follow-up * (number of participants - 0.5 * number of SAEs))) and adjusting for 231 
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direct renin inhibitor trial (yes/no), comparison type (placebo, different ATC class to 3-character, 232 
different ATC class to 5-character), phase (3 or 4) and outcome type (hard or soft). The adjusted 233 
model was the pre-specified primary analysis. Models were fitted using Rstanarm to allow fitting of 234 
the random intercept for the trials. 235 
We also used Poisson regression to model the age and sex specific rate of unplanned hospital 236 
admission or death in the 3 years following initiation of RAAS drugs in SAIL. This model fitted the 237 
data well (appendix p 1-4) and the covariates and variance covariance matrix were exported from 238 
the SAIL secure platform to allow us to calculate the expected number of hospitalisations and deaths 239 
for each trial population. Having calculated the expected rate of hospitalisations and deaths (as a 240 
proxy for SAEs), we calculated the ratio of expected to observed SAEs. We used the truncated 241 
normal distribution to estimate the age distribution for each trial based on the reported mean age as 242 
well as any age cut-offs used as exclusion criteria. In a previous analysis of trial IPD (including trials 243 
with the same eligibility criteria as those in this sample) the truncated normal distribution was found 244 
to accurately represent the age distribution of trials in this context.12 We obtained uncertainty 245 
intervals for the observed/expected ratio for each trial as follows. We obtained 10,000 samples of 246 
the intercept, age and sex coefficients by sampling from a multivariate normal distribution where 247 
the parameters were the point estimates and variance covariance matrix for the SAIL Poisson 248 
regression models. For each sample we applied the coefficients to the age-sex distribution of each 249 
trial to obtain 10,000 samples from the distribution of the expected count. We then divided each of 250 
these by each of 10,000 samples from a Poisson distribution (where the parameter was the observed 251 
count) to obtain 10,000 samples representing the uncertainty distribution for the 252 
observed/expected ratio, which we summarised by the mean, 2.5th and 97.5th centiles.  253 
We obtained the standardised ratio of hospitalisations and deaths in the community and SAEs in the 254 
trials by treating the log of the expected count (which was obtained by applying the SAIL-derived 255 
age-sex specific rates to the age-sex distribution of each trial) as an offset term in the regression 256 
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model (hierarchical Poisson regression model as described above). The first model compared 257 
standard and older people trials. The second further adjusted for trial characteristics. 258 
We performed three sets of sensitivity analyses. First, in view of the small number of older people 259 
trials, we re-ran the regression models having excluded each trial in turn to examine the sensitivity 260 
of the findings to trial characteristics. The second sensitivity analysis explored the impact of possible 261 
misclassification of the indication for RAAS treatment within the community cohort. For this, in 262 
addition to excluding participants with recent myocardial infarction or stroke (as in the main 263 
analysis), we also excluded any participant with a previous diagnosis of diabetes mellitus, heart 264 
failure, or chronic kidney disease. We then repeated all analyses comparing trials to the community 265 
cohort. Finally, as the trial follow-up periods were shorter than the observation time of the 266 
community cohort, we repeated all analyses limiting follow-up of the community sample to the first 267 
90 days following initial prescription (to mirror the median follow-up in the older people’s trials) and 268 
analysing first event only (i.e. censoring at 90 days, first hospitalisation or death, whichever 269 
happened first). 270 
All analyses were performed using R version 3.6.1. The full analysis code and all data are available at 271 
github repository https://github.com/dmcalli2/adverse_events_older_people. 272 
The funder of the study had no role in study design, data collection, data analysis, data 273 
interpretation, or writing of the report. All authors had full access to all of the data. DM had the final 274 




We included 110 trials, of which 11 (10%) were trials in older people and 99 (90%) were standard 277 
trials which did not focus specifically on older people. Trial details are summarised in table 1. The 278 
median number of SAEs per trial was 7.5 (interquartile range [IQR] 3-14). The median rate of SAEs 279 
per person per year was 0.18 (IQR 0.12-0.29) in the older people trials and 0.11 (0.08-0.18) in the 280 
standard trials. These SAE rates refer to the whole trial population, as among the placebo-controlled 281 
trials SAE rates were similar between treatment and control arms. 282 
Table 1: Summary of included trials  
 Standard trials (n = 99) Older-people trials (n 
= 11) 
Community 
Mean age Median of trial mean 
ages: 55.6 (IQR 53.7 to 
57.0) 
Median of trial mean 
ages:  73.1 (IQR 71.6 
to 74.2) 
60.6 (sd 13.9) 
% women  Median 45% (IQR 40% 
to 49%) 
Median 55% (IQR 52% 
to 55%) 
50.3% 












  Placebo 









  3 









  Hard 








Trial sample size Median 722 (474 to 
1124) 
Median 754 (388 to 
884) 
- 
Trial follow-up (days) Median 63 (56 to 98) Median 98 (56 to 252) - 
Footnote: Data for each trial are available at 
https://github.com/dmcalli2/adverse_events_older_people including data on baseline blood 
pressure (4/11 older people’s trials and 46/99 standard trials), comorbidity status (3/11 older 
people’s trials and 37/99 standard trials), and ethnicity (2/11 older people’s trials and 39/99 




Before adjusting for trial characteristics, the incident rate ratio (95% credible interval) for older 284 
versus standard trials was 1.57 (0.95 to 2.57). After adjusting for trial characteristics including trial 285 
drug, type of comparison, trial phase and type of outcome, older-people trials had a higher incidence 286 
of SAEs (IRR 1.74, 95% credible interval 1.03-2.92) than did standard trials.  287 
The expected age- and sex-adjusted rates of all-cause hospitalisation and death among people with 288 
hypertension starting RAAS drugs in routine clinical practice is shown on figure 3. Coloured points 289 
show the observed rate of SAEs in each trial, while the black points show the expected SAE rate 290 
obtained by applying community all-cause hospitalisation and death rates to the age and sex 291 
distribution of each trial (each coloured point has a black point which is its pair, but lines connecting 292 
these are not shown for clarity). The observed rates were consistently lower than the expected rates 293 
(shown by the coloured points in figure 3).  294 
  295 
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Figure 3: Observed versus expected SAEs per trial 
 
Legend: The observed rate of SAE per trial is shown by the coloured points (red = standard, blue = older people). Points 
are plotted at the mean age for the trial. The expected number of hospitalisations and deaths for each trial, based on 
the age/sex specific rates from SAIL applied to the age/sex distribution of the trial, is shown by the black points. Trial 
sample size for trials is indicated by the size of the coloured points. 
 296 
A formal comparison of the ratio between the observed SAE rate and the expected rate of 297 
hospitalisation and death for each trial (adjusted for age and sex) is shown in figure 4. For all but one 298 
of the trials, the rate of SAEs was lower than the expected rate of hospitalisation and deaths given 299 
the age/sex distribution of trial participants. There was considerable heterogeneity in the calculated 300 
ratios, both within the older people’s trials and the standard trials. However, across all trials, the 301 
reported rate of SAEs was considerably lower than would be expected to occur if the trials were 302 
representative of people with hypertension taking RAAS drugs in the community. The standardised 303 
ratio (SR) was 3.70 (95% CI 3.12-4.55) for ‘standard trials’ and 4.35 (95% CI 2.56-7.69) for ‘older 304 
people trials’, indicating that hospitalisations and deaths occurred more than four times more 305 
frequently among people taking RAAS drugs in the community than SAEs occurred in trials.  The 306 
magnitude of risk increase for SAEs in community patients taking RAAS did not differ, when 307 
comparing standard and older people trials (ratio of SR 1.16; 95% CI 0.67-2.04). The results were 308 
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similar after adjusting for agent, type of outcome (clinical endpoint yes/no), type of comparison and 309 
phase (adjusted SR 4.00; 95% CI 2.50-6.25 for standard trials, 4.55; 95% CI 2.08-10.00 for older 310 
people’s trials, and ratio of SRs 1.11; 95%CI 0.59-2.04). 311 
In the first sensitivity analysis, the effect estimates were similar on leaving out each trial in turn. In 312 
the second sensitivity analysis, the difference between trials and the community was similar after 313 
further excluding people with diabetes mellitus, heart failure or chronic kidney disease from the 314 
community sample, to minimise the risk of misclassification of the indication for RAAS treatment 315 
(see appendix p 5-7). In the final sensitivity analysis, limiting the community follow-up to 90 days to 316 
mirror that of the trials, the difference between trials and community was also similar (see appendix 317 







Figure 4 legend: Each point (with 95% confidence intervals) shows the ratio of expected all-cause hospitalisations or deaths 319 
(given the estimated age/sex distribution of each trial) to the observed SAE count in each trial. Four trials reported no SAEs 320 
and the ratio was therefore infinite, and are excluded from this plot. The plot also excludes a further 7 trials with only one 321 
reported SAE and ratios >50. 322 




In this analysis of trials of RAAS drugs for hypertension, trials specifically recruiting older people (all 325 
>60 years, mean age >70) had a significantly higher incidence of SAEs than standard trials after 326 
adjusting for trial characteristics. This suggests that trials of older people do recruit participants with 327 
a higher baseline risk of adverse health outcomes.  328 
Nonetheless, in both trials of older people and standard trials, the rate of SAEs was substantially 329 
lower than expected based on the incidence of hospitalisation and death (which would be classed as 330 
SAEs in all trials) in people with hypertension being treated in the community. The difference was 331 
large, with rates of hospitalisations and death in the community on average four times greater than 332 
the rate of SAEs in the trials. This suggests that, even accounting for age and sex, participants in 333 
hypertension trials and people with hypertension in the community are very different populations. 334 
These differences may reflect differences in the study setting (although hospitalisation rates in the 335 
UK are comparable with other OECD countries) as well as demographic and clinical differences in the 336 
included populations. These differences may include comorbidity and underlying health status (with 337 
differences driven in part by trial exclusion criteria) as well as other factors such as ethnicity, 338 
socioeconomic status, hypertension severity, healthcare utilisation and medication adherence. Of 339 
note, many of these factors were not reported in the included trials.  340 
This difference between trial and community populations was similar for older-people trials and for 341 
standard trials. This does not necessarily mean trial findings are inapplicable. Relative treatment 342 
benefits estimated in trials will often be applicable even where there are differences between trial 343 
and target populations,24 but net benefit may still vary because adverse events are more common, 344 
and optimal choice of drug may be affected by comorbidity and co-prescribing. This suggests that 345 
clinical guideline developers are correct to be cautious when applying trial evidence to community 346 
populations. This is particularly true for older, multimorbid or frailer populations, and remains true 347 
even when trials are deliberately targeted at older people. 348 
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While these findings suggest that trials are under-representative in terms of underlying risk of 349 
adverse health outcomes, there are two alternative explanations which could also contribute to the 350 
difference between trials and the community sample. First, trials may under-report the true 351 
incidence of SAEs. Despite reporting guidelines,19 there is inconsistency in how SAEs are reported.25 352 
On the other hand, trial recorded SAEs include other events meaning that trial SAE incidence would 353 
be expected to be higher than the community events examined. Second, our community sample 354 
may include people taking RAAS for other indications, for whom the risk of hospitalisations and 355 
deaths may be higher. For this reason, the primary analysis excluded people with recent myocardial 356 
infarction or stroke, and sensitivity analysis excluded people with a history of diabetes, chronic 357 
kidney disease, or heart failure, with consistent findings across all analyses.  Nonetheless, we cannot 358 
be certain about the true indication for starting RAAS drugs from routine data alone. Both 359 
underreporting of SAEs and misclassification of the community comparison may bias our estimation 360 
of the difference between trials and community samples in the direction that we observed. 361 
However, the difference between trials and community populations was large (median 4-times 362 
higher rate in the community than in trials) and it is likely that the observed lower rates of SAEs in 363 
trial populations is true.   364 
Our findings have implications for interpreting trials that specifically recruit older people. On one 365 
hand, trials focusing on older people are likely to be helpful in informing treatment decisions as they 366 
successfully recruit older people at a higher risk of serious adverse events than standard trials, thus 367 
capturing some of the increased risk experienced. However, concerns about trial representativeness 368 
are still well founded, as suggested by the difference between SAEs and hospitalisation and death 369 
rates in the community. We observed that the difference between trials and community event rates 370 
were similar in both trials of older people and standard trials, suggesting they were similarly under-371 
representative. This suggests that trials focussing on older people present only part of the solution 372 
to informing treatment decisions in older people, particularly those at higher risk of adverse health 373 
outcomes, such as people living with frailty. 374 
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The higher rate of hospitalisations and deaths in the community population has some important 375 
implications for managing hypertension in older people. First this finding is likely to reflect a higher 376 
prevalence and severity of frailty in community populations compared to trials, which may modify 377 
the relationship between hypertension and cardiovascular risk.4 We previously showed, in an 378 
individual-level participant data analysis, that frailty is associated with SAEs in trials.13 Furthermore, 379 
frailty in participants in cardiovascular trials is associated with adverse cardiovascular outcomes 380 
independently of traditional risk factors.26 While frailty has been shown to be present in trials for 381 
hypertension in older people,8,9 frailty in these trials is thought to be less severe than in the 382 
community.2 People living with severe frailty are likely to be excluded from clinical trials, however 383 
such individuals are commonly prescribed these medications in the community, often in the context 384 
of polypharmacy. The applicability of trial evidence, even those recruiting older people, needs 385 
careful consideration when applied to a broader population. It is also likely that such evidence is 386 
insufficient to inform treatment decisions in some patient groups, such as people living with severe 387 
frailty. 388 
Second, the difference in SAEs between trial and community populations may impact the net benefit 389 
of treatment when used in routine clinical practice.27 For example, higher competing mortality risks 390 
in the community may mean that benefits in terms of absolute treatment effects (based on trial 391 
participants) are overestimated.28 Also, if drug-related SAEs were more common in the community 392 
(for example, among people living with frailty) this may reduce the net benefit of treatment.29,30 For 393 
example, even if drugs reduce cardiovascular outcomes, net benefit may get smaller if SAE rates 394 
increase rapidly with age. Quantifying net benefit would require analysis of differential treatment 395 
effectiveness and also treatment-related SAEs, neither of which are possible with this data. 396 
However, our findings do indicate that clinicians and guideline developers should be cautious when 397 
applying trial estimates of benefit to the wider population. 398 
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Strengths of this study include a systematic identification of registered trials. By searching using a 399 
trial register and hand-searching clinical study reports we were able to include both published and 400 
unpublished trials, limiting publication bias. Limiting our search to clincaltrials.gov may have resulted 401 
in a small proportion of studies not being included in our investigation. However, clinicaltrials.gov is 402 
the largest international trial registry and trial pre-registration is required both for publication in 403 
high-impact journals and to qualify as evidence for regulatory agencies such as the United States 404 
Food and Drug Administration.18 Moreover, it provided a single sampling frame from which we could 405 
draw all older people and standard trials. Limiting our search to trials started after 1999 ensured 406 
that trials were conducted in a similar time-period to the community comparison, and is a period in 407 
which trial registration is increasingly commonplace, however this will have led to the exclusion of 408 
earlier trials, including of commonly-prescribed RAAS drugs such as angiotensin-converting enzyme 409 
inhibitors. The systematic comparison of SAE rates with hospitalisation and death rates in the 410 
community for people with hypertension is novel and builds upon previous studies of trial 411 
representativeness by comparing actual health-related outcomes rather than inclusion criteria. 412 
Nonetheless, comparing SAEs to hospitalisations and deaths is not an exact like-for-like comparison. 413 
SAEs have a broader definition which includes events perceived to be life threatening as well as 414 
events leading to impairment or disability (which may not necessarily result in hospitalisation). 415 
However, hospitalisations and deaths are, by definition, SAEs and so any bias is very likely towards 416 
under-estimating the difference between trial and community rates. Trial data were reported 417 
inconsistently, and for some trials we had to estimate the observation time in the trial (based on 418 
follow-up length and the SAE rate). Also, as we have highlighted above, we were not able to verify 419 
the indication for RAAS drugs in the community. While we excluded participants with recent events 420 
which would be alternative indications, there may be some participants prescribed RAAS drugs for 421 
reasons other than hypertension. This study focussed on RAAS drugs for hypertension, and the 422 
findings may not necessarily be generalisable to other drugs or indications, particularly as SAE rates 423 




Our study shows that participants in hypertension trials experience substantially lower rates of 426 
serious adverse health outcomes than people with hypertension treated with similar drugs in the 427 
community. Our work suggests assessment of the rate of SAEs, when compared to the expected rate 428 
from representative “target” populations, may be a useful metric of trial representativeness. Our 429 
findings also show that the problem of under-representativeness is not resolved by recruiting older 430 
people to trials, as both older people trials and standard trials were also under-representative in 431 
terms of SAEs. This observation emphasises the need for developing approaches to design and 432 
execution which enable older people living with frailty to become trial participants. 433 
  434 
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